Stapokibart Sales Forecast, and Market Size Analysis - 2034

Key Factors Driving Stapokibart Growth

1. Approval in a Large and Rapidly Growing Atopic Dermatitis Market

Stapokibart received its first approval in China in September 2024 for adults with moderate-to-severe atopic dermatitis inadequately controlled by topical therapies. This gives Keymed access to one of the world's largest AD patient populations, where biologic penetration remains relatively low compared with Western markets.

China's atopic dermatitis prevalence has increased substantially over the past decade, and the demand for biologic therapies continues to grow as diagnosis rates and specialist access improve.

2. Strong Phase III Efficacy Comparable to Leading Global Biologics

The pivotal Phase III trial demonstrated highly competitive efficacy:

• 66.9% of patients achieved EASI-75 at Week 16 versus 25.8% with placebo.
• 44.2% achieved Investigator's Global Assessment (IGA) 0/1 versus 16.1% with placebo.
• Significant improvements in itch and skin clearance were observed across endpoints.

These efficacy levels compare favorably with established IL-4/IL-13 pathway inhibitors and support physician confidence in prescribing the drug.

3. Durable Long-Term Responses Support Chronic Use

Long-term treatment is critical in AD because patients often require therapy for years.

At Week 52:

• 92.5% of continuously treated patients maintained EASI-75 responses.
• 67.3% achieved IGA 0/1.
• 67.3% achieved clinically meaningful itch reduction.

Importantly, most adverse events were mild-to-moderate, and no new long-term safety signals emerged. Strong durability supports prolonged treatment duration and recurring revenue.

4. Potential Pricing Advantage Versus Imported Biologics

A major commercial opportunity is stapokibart's position as a domestically developed Chinese biologic.

Historically, locally developed biologics in China have often achieved broader access through more competitive pricing and potential reimbursement advantages compared with imported therapies. If stapokibart gains broad reimbursement coverage through China's healthcare system, uptake could accelerate significantly among biologic-eligible AD patients. While formal pricing strategies continue to evolve, this remains a key competitive advantage.

5. Expansion into Additional Type 2 Inflammatory Diseases

The IL-4/IL-13 pathway is implicated in multiple allergic and inflammatory diseases beyond AD.

Publicly disclosed development programs and scientific discussions have included:

• Allergic rhinitis
• Chronic rhinosinusitis with nasal polyps
• Asthma
• Other type 2 inflammatory conditions

Successful expansion into even one additional major indication could substantially increase the drug's commercial opportunity beyond dermatology.

Stapokibart Recent Developments

In December 2024, Keymed Biosciences Inc. announced the National Medical Products Administration (the "NMPA") of China had approved the supplemental New Drug Application (the "sNDA") of Stapokibart (anti-IL-4Ra monoclonal antibody, trade name: Kangyueda, R&D codename: CM310), for the treatment of chronic rhinosinusitis with nasal polyposis.

"Stapokibart Sales Forecast, and Market Size Analysis - 2034" report provides comprehensive insights of Stapokibart for approved indication like Allergic rhinitis, Atopic dermatitis, and Rhinosinusitis; as well as potential indication like Prurigo nodularis, Asthma, and Chronic obstructive pulmonary disease in the 7MM. A detailed picture of Stapokibart's existing usage in approved and anticipated entry and performance in potential indications in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2020 -2034 is provided in this report along with a detailed description of the Stapokibart for approved and potential indications. The Stapokibart market report provides insights about Stapokibart's sales forecast, mechanism of action (MoA), dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of historical and current Stapokibart performance, future market assessments inclusive of the Stapokibart market forecast analysis for approved and potential indications in the 7MM, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in respective indications. It also provides analysis of Stapokibart sales forecasts, along with factors driving its market.

Stapokibart Drug Summary

Stapokibart (CM310) is a humanized monoclonal antibody developed by Keymed Biosciences that targets the interleukin-4 receptor alpha (IL-4Ra), thereby blocking the signaling of both IL-4 and IL-13, two key cytokines involved in type 2 inflammation. Administered by subcutaneous injection, stapokibart is being developed and commercialized for the treatment of allergic and inflammatory diseases, particularly moderate-to-severe Atopic Dermatitis. By inhibiting IL-4 and IL-13 pathways, the drug reduces inflammation, pruritus, and skin barrier dysfunction associated with atopic dermatitis. Clinical studies have demonstrated significant improvements in skin clearance, itch reduction, and quality of life, with a favorable safety and tolerability profile. As a potential competitor to established IL-4Ra-targeting biologics, stapokibart represents a promising therapeutic option for patients requiring long-term systemic control of type 2 inflammatory diseases. The report provides Stapokibart's sales, growth barriers and drivers, post usage and approvals in multiple indications.

Scope of the Stapokibart Market Report

The report provides insights into:

• A comprehensive product overview including the Stapokibart MoA, description, dosage and administration, research and development activities in approved indications like Allergic rhinitis, Atopic dermatitis, and Rhinosinusitis; as well as potential indication like Prurigo nodularis, Asthma, and Chronic obstructive pulmonary disease.
• Elaborated details on Stapokibart regulatory milestones and other development activities have been provided in Stapokibart market report.
• The report also highlights Stapokibart's cost estimates and regional variations, reported and estimated sales performance, research and development activities in approved and potential indications across the United States, Europe, and Japan.
• The Stapokibart market report also covers the patents information, generic entry and impact on cost cut.
• The Stapokibart market report contains current and forecasted Stapokibart sales for approved and potential indications till 2034.
• Comprehensive coverage of the late-stage emerging therapies for respective indications.
• The Stapokibart market report also features the SWOT analysis with analyst views for Stapokibart in approved and potential indications.

Methodology:

The Stapokibart market report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

Stapokibart Analytical Perspective by DelveInsight

• In-depth Stapokibart Market Assessment

This Stapokibart sales market forecast report provides a detailed market assessment of Stapokibart for approved indication like Allergic rhinitis, Atopic dermatitis, and Rhinosinusitis; as well as potential indication like Prurigo nodularis, Asthma, and Chronic obstructive pulmonary disease in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides current and forecasted Stapokibart sales data uptil 2034.

• Stapokibart Clinical Assessment

The Stapokibart market report provides the clinical trials information of Stapokibart for approved and potential indications covering trial interventions, trial conditions, trial status, start and completion dates.

Stapokibart Competitive Landscape

The report provides Insights on competitors and marketed products within the domain, along with a summary of emerging products and their respective launch dates, posing significant competition in the market.

Stapokibart Market Potential & Revenue Forecast

• Projected market size for the Stapokibart and its key indications
• Estimated Stapokibart sales potential (Stapokibart peak sales forecasts)
• Stapokibart Pricing strategies and reimbursement landscape

Stapokibart Competitive Intelligence

• Number of competing drugs in development (pipeline analysis)
• Stapokibart Market positioning compared to existing treatments
• Stapokibart Strengths & weaknesses relative to competitors

Stapokibart Regulatory & Commercial Milestones

• Stapokibart Key regulatory approvals & expected launch timelines
• Commercial partnerships, licensing deals, and M&A activity

Stapokibart Clinical Differentiation

• Stapokibart Efficacy & safety advantages over existing drugs
• Stapokibart Unique selling points

Stapokibart Market Report Highlights

• In the coming years, the Stapokibart market scenario is set to change due to strong adoption, increased prescriptions and broader uptake in multiple immunological indications; which would expand the size of the market.
• The Stapokibart companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence Stapokibart's dominance.
• Other emerging products for Allergic rhinitis, Atopic dermatitis, and Rhinosinusitis; as well as potential indication like Prurigo nodularis, Asthma, and Chronic obstructive pulmonary disease are expected to give tough market competition to Stapokibart and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of Stapokibart in approved and potential indications.
• Analyse Stapokibart cost, pricing trends and market positioning to support strategic decision-making in the immunology landscape.
• Our in-depth analysis of the forecasted Stapokibart sales data uptil 2034 will support the clients in decision-making process regarding their therapeutic portfolio by identifying the overall scenario of Stapokibart in approved and potential indications.

Key Questions:

• What is the class of therapy, route of administration and mechanism of action of Stapokibart? How strong is Stapokibart's clinical and commercial performance?
• What is Stapokibart's clinical trial status in each individual indications such as Allergic rhinitis, Atopic dermatitis, and Rhinosinusitis; as well as potential indication like Prurigo nodularis, Asthma, and Chronic obstructive pulmonary disease and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the Stapokibart Manufacturers?
• What are the key designations that have been granted to Stapokibart for approved and potential indications? How are they going to impact Stapokibart's penetration in various geographies?
• What is the current and forecasted Stapokibart market scenario for approved and potential indications? What are the key assumptions behind the forecast?
• What are the current and forecasted sales of Stapokibart in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain) and the United Kingdom, and Japan?
• What are the other emerging products available and how are these giving competition to Stapokibart for approved and potential indications?
• Which are the late-stage emerging therapies under development for the treatment of approved and potential indications?
• How cost-effective is Stapokibart? What is the duration of therapy and what are the geographical variations in cost per patient?